Related Experiment Video

Updated: Aug 6, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Targeting HER2 Epitopes

Sumanta Kumar Pal1, Mark Pegram

  • 1Division of Hematology-Oncology, Department of Medicine, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA. spal@mednet.ucla.edu

Seminars in Oncology
|August 8, 2006
PubMed

Insights

Targeting the HER2 receptor, a key factor in many cancers, involves various therapies. Monoclonal antibodies, peptidomimetics, and RNA aptamers inhibit cancer cell growth, with potential synergy when combined.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Variable human epidermal growth factor receptor 2 (HER2) expression is crucial in several cancers.
  • Targeted therapies aim to inhibit HER2 and its downstream signaling pathways.

Purpose of the Study:

  • To review HER2-targeting agents including monoclonal antibodies, peptidomimetics, and RNA aptamers.
  • To explore the potential synergistic interactions of these agents.

Main Methods:

  • Literature review of HER2-targeting therapeutic modalities.
  • Analysis of experimental data on antibody, peptidomimetic, and aptamer efficacy.
  • Examination of recent findings on combination therapy interactions.

Main Results:

  • Monoclonal antibodies (trastuzumab, pertuzumab) and peptidomimetic agents inhibit HER2-positive cancer cell growth.
  • RNA aptamers also bind HER2 extracellular epitopes, leading to growth inhibition.
  • Experimental models suggest synergistic effects when HER2-targeting agents are combined.

Conclusions:

  • HER2-targeting agents offer diverse mechanisms for inhibiting cancer progression.
  • Combination therapies may enhance efficacy through synergistic interactions.
  • Further research into combined HER2-targeted treatments is warranted.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.